OakChart

Insight Molecular Diagnostics Inc

IMDXHealthcare·Diagnostics & Research·USA·Micro·NASD·Nov 10 • 3:59 PM ET

2.470.00 (0.00%)
2026-11-11 14:58 CET
Market cap
80.83 USD m
Revenue, TTM
1.67 USD m
Net income, TTM
-49.36 USD m
Free cash flow, TTM
-30.88 USD m
EPS diluted, TTM
-1.49
P/E
-
Compare

Price

IMDX against its 20, 50 and 200-day averages
2050200beatmissearnings
4.006.00583K1.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26IMDXclose 2.4720-day 2.8650-day 3.39200-day 4.602.47

71.0% under 8.51 on 12 Nov 2025. Last 15 sessions, 38.6% high to low

Profile

IMDX
52-week range, 2% of the way up
2.358.51

Insight Molecular Diagnostics, Inc. is a diagnostics technology company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The company was founded in September 2009 and is headquartered in Nashville, TN.

Employees58
IPODec 30, 2015
Beta1.88
ATR, 14d0.29
Rel volume0.00
Short float10.03%
Insider own68.77%
Inst own18.85%

Snapshot

6 groups

Valuation

Index-
Market Cap80.83M
Enterprise Value64.97M
Income-49.36M
Sales1.67M
Book/sh-0.65
Cash/sh0.56
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees58
IPODec 30, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S48.40
P/B-
P/C4.37
P/FCF-
EV/EBITDA-
EV/Sales38.90
Quick Ratio1.98
Current Ratio2.00
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.49
EPS next Y-0.86
EPS next Q-0.24
EPS this Y45.21%
EPS next Y4.65%
EPS next 5Y27.84%
EPS past 3/5Y50.09% 29.01%
Sales past 3/5Y61.76% 27.24%
EPS Y/Y TTM57.26%
Sales Y/Y TTM-60.77%
EPS Q/Q-0.72%
Sales Q/Q-53.86%
EarningsNov 16 AMC
EPS/Sales Surpr.-22.05% -32.20%

Ownership

Insider Own68.77%
Insider Trans0.00%
Inst Own18.85%
Inst Trans-6.75%
ROA-123.46%
ROE-23603.11%
ROIC-
Gross Margin-93.38%
Oper. Margin-2217.90%
Profit Margin-2955.63%
SMA20-13.52%
SMA50-27.20%
SMA200-46.27%
Trades-

Technical

Shs Outstand32.62M
Shs Float10.22M
Short Float10.03%
Short Ratio4.22
Short Interest1.03M
52W High8.51 -70.98%
52W Low2.35 5.33%
Volatility11.47% 9.56%
ATR (14)0.29
RSI (14)32.36
Beta1.88
Rel Volume0.00
Avg Volume243.18K
Volume0

Performance

Perf Week-9.85%
Perf Month-22.08%
Perf Quarter-45.11%
Perf Half Y-50.40%
Perf YTD-67.07%
Perf Year-63.68%
Perf 3Y-11.15%
Perf 5Y-96.31%
Perf 10Y-97.30%
Recom1.80
Target Price8.25
Prev Close2.47
Price2.47
Change %0.00%

Analyst ratings

latest 10 of 17
DateActionAnalystRating changeTargetImplied
Mar 28, 2025InitiatedLLake StreetBuy$5+102.4%
May 24, 2022DowngradeSStephensOverweight → Equal-Weight
Mar 14, 2022DowngradeKKeyBanc Capital MarketsOverweight → Sector Weight
Jan 07, 2022InitiatedSStephensOverweight$3.10+25.5%
Jan 06, 2022ResumedPPiper SandlerOverweight$3.10+25.5%
Mar 17, 2021ResumedNNeedhamBuy$8+223.9%
Jan 07, 2021UpgradeTThe Benchmark CompanySpeculative Buy → Buy$6+142.9%
Dec 16, 2020UpgradePPiper SandlerNeutral → Overweight$2 → $4+61.9%
Nov 30, 2020InitiatedBBTIG ResearchBuy$5+102.4%
Nov 10, 2020InitiatedKKeyBanc Capital MarketsOverweight$5+102.4%

Peers

Mkt cap
TickerCompanyMkt cap
CDNACaredx Inc4.31B
NTRANatera Inc46.33B
BDSXBiodesix Inc105.90M
VCYTVeracyte Inc1.98B
XGNExagen Inc135.29M
PSNLPersonalis Inc1.72B
TMOThermo Fisher Scientific Inc265.85B
CSTLCastle Biosciences Inc1.06B
GHGuardant Health Inc21.17B
MDXHMDxHealth SA13.56M

Insider trading

7 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
BROADWOOD PARTNERS, L.P.10% OwnerApr 23 '26Buy3.50280,381982,03412,395,081Apr 27 07:08 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 27 '26Buy3.64250,923913,13412,684,884Apr 27 07:08 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 24 '26Buy3.5338,880137,08312,433,961Apr 27 07:08 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 16 '26Buy3.45102,057351,65812,033,896Apr 20 07:24 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 20 '26Buy3.8840,690157,96712,114,700Apr 20 07:24 PM
BROADWOOD PARTNERS, L.P.10% OwnerApr 17 '26Buy3.5740,114143,25112,074,010Apr 20 07:24 PM
BROADWOOD PARTNERS, L.P.10% OwnerFeb 10 '26Buy5.75521,7392,999,99911,931,839Feb 12 07:49 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 204
  • iMDx to Release Third Quarter Results on November 16, 2026 (GlobeNewswire) -7.17%
  • iMDx Welcomes New Diagnostics Sales Leader to Prepare for Planned GraftAssureDx Launch (GlobeNewswire) -6.69%
  • iMDx to Participate in Virtual U.S. Bancorp I BTIG Kidney Health Forum with KOL Discussion and Investor Meetings (GlobeNewswire) -5.93%
  • iMDx to Participate in Lake Street 10th Annual Best Ideas Growth "BIG10" Conference (GlobeNewswire)
  • Insight Molecular Diagnostics to Host Virtual KOL Event on August 17, 2026: Moving Toward In-House Heart Transplanted Organ Rejection Testing (GlobeNewswire) -7.13%
  • Loading…
  • Insight Molecular Diagnostics: Q2 Earnings Snapshot (Associated Press)
  • IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx (GlobeNewswire)
  • iMDx to Release Second Quarter Results on August 10, 2026 and Attend Needham Virtual MedTech & Diagnostics 1x1 Conference (GlobeNewswire)
  • iMDx GraftAssure Assay Guides Use of Potentially Kidney-Graft-Saving Drug in New Lancet Group Publication (GlobeNewswire)
  • Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay Portfolio (GlobeNewswire)
  • IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper (GlobeNewswire)
  • iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant (GlobeNewswire)
  • Favorable Head-to-Head Data on iMDx's GraftAssure with Competing NGS Assay Published in Clinical Chemistry (GlobeNewswire) -6.67%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-16--0.236--0.245
2026Q22026-08-10-0.310-0.254-0.3100.240.354
2026Q12026-05-13-0.120-0.262-0.1240.030.234
2025Q42026-03-26-0.720-0.238-0.7161.140.294
2025Q32025-11-10-0.200-0.210-0.3390.260.284
2025Q22025-08-11-0.300-0.230-0.3040.520.294
2025Q12025-05-12-0.188-0.238-0.2602.140.134
2024Q42025-03-24-1.930-0.400-1.9281.490.103
2024Q32024-11-12-0.402-0.437-0.9840.120.183
2024Q22024-08-08-0.385-0.560-0.3560.100.322
2024Q12024-05-15-0.618-0.670-1.1300.180.353
2023Q42024-04-12-2.270-0.700-1.9600.310.232
2023Q32023-11-09-0.810-1.008-0.8100.430.314
2023Q22023-08-10-1.070-1.298-21.3700.460.364
2023Q12023-05-110.400-1.8000.4020.300.355
2022Q42023-03-31-8.000-1.876-8.0001.101.425

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2017FY-12.800-12.950-12.8000.000.00
2018FY-8.400-7.800-8.3240.000.00
2019FY-8.800-7.320-8.7440.000.00
2020FY-9.200-9.650-9.1431.221.50
2021FY-14.400-8.200-14.4177.737.82
2022FY-13.200-7.170-13.2535.605.94
2023FY-3.750-1.300-3.7541.501.42
2024FY-4.660-2.740-4.6611.880.50
2025FY-1.650-1.145-1.6504.063.23
2026FY--0.904--0.97
2027FY--0.862--6.66
2028FY--0.620--27.25

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-065200.240.100.30
2026Q3S2026-10-285100.240.100.30
2026Q3S2026-10-255120.240.100.30
2026Q3S2026-09-215130.240.100.30
2026Q3S2026-08-215030.220.000.30
2026Q3S2026-08-144030.270.220.30
2026Q3S2026-08-114110.440.220.94
2026Q3S2026-08-104000.540.300.94
2026Q3S2026-08-074010.460.250.94
2026Q3S2026-07-284000.540.300.94
2026Q3S2026-06-104110.540.300.94
2026Q3S2026-05-144210.540.300.94
2026Q3S2026-04-154110.650.301.40
2026Q3S2026-03-274110.660.301.40

Estimate history

EPS, annual-12.8-8.324-8.744-9.143-14.417-13.253-3.754-4.661-1.648-1.4854
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.356-0.984-1.928-0.26-0.304-0.339-0.716-0.124-0.306
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0001.2162.1980.9581.5031.8814.0551.67
Period201720182019202020212022202320242025TTM
Sales, quarterly0.1040.1151.4862.1380.5180.261.1390.0320.239
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual1.5732.0332.8523.4564.6125.9328.26117.45328.68332.623
Period201720182019202020212022202320242025MRQ
Shares, quarterly13.36813.37417.45328.59928.61728.62528.68332.28632.623
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue1.674.051.881.500.962.201.220.000.00
Cost of Goods Sold Incl. D&A3.233.872.552.606.204.981.850.340.56
Gross Profit-1.560.19-0.67-1.10-5.24-2.79-0.64-0.34-0.56
Selling, General and Administrative Excl. Other35.4830.7722.5821.1723.5920.9931.0321.8914.02
Research and Development17.7814.668.807.886.964.578.646.795.77
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-37.04-30.58-23.25-22.27-28.83-23.77-31.67-22.24-14.58
Interest Expense0.100.110.080.050.080.210.25-0.22
Unusual Expense13.2620.5537.621.65-10.3628.58-2.251.101.05
Net Income Before Taxes-49.36-50.22-60.66-24.86-18.61-52.87-31.19-22.43-15.75
Income Taxes0.000.000.000.000.00-9.26-1.250.000.00
Consolidated Net Income-49.36-50.22-60.66-24.86-18.61-43.61-29.93-22.43-15.75
Net Income From Continuing Operations-49.36-50.22-60.66-24.86-18.61-43.61-29.93-22.43-15.75
Net Income-49.36-50.22-60.93-28.72-73.42-64.10-29.93-22.43-15.75
EPS (Recurring)-1.09-1.18-2.65-3.60-14.56-9.92-9.62-8.44-7.94
EPS (Basic, Before Extraordinaries)-1.49-1.65-4.66-3.75-13.25-14.42-9.14-8.74-8.32
EPS (Diluted)-1.49-1.65-4.66-3.75-13.25-14.42-9.14-8.74-8.32
EBITDA-34.60-28.38-21.68-20.59-23.61-19.57-31.27-21.89-14.02
Non-Operating Income (Expense)1.041.010.29-0.89-0.07-0.31-1.520.920.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.522.221.752.7410.045.405.073.001.48
Price To Sales Ratio129.8456.3716.5412.7337.1187.79128.69--
Gross Margin-93.384.69-35.41-73.32-546.76-126.71-52.55--
Operating Margin-2,217.90-754.08-1,235.89-1,481.57-3,009.50-1,081.62-2,604.11--
Net Margin-2,955.63-1,238.52-3,239.02-1,911.04-7,664.09-2,916.15-2,461.51--
Shares Outstanding32.6228.6817.458.265.934.613.462.852.03
Market Capitalization80.8380.8340.0720.6538.06200.14165.19128.3256.12

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.240.031.140.260.522.141.490.12
Cost of Goods Sold Incl. D&A0.720.641.190.680.711.281.440.38
Gross Profit-0.48-0.61-0.05-0.42-0.190.860.04-0.27
Selling, General and Administrative Excl. Other8.609.739.907.256.856.785.476.11
Research and Development4.114.605.523.552.962.641.922.58
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-9.09-10.33-9.95-7.67-7.04-5.92-5.42-6.38
Interest Expense0.020.020.030.030.030.030.030.03
Unusual Expense2.31-5.9213.483.382.800.8828.207.14
Net Income Before Taxes-11.26-4.29-22.95-10.85-9.74-6.67-33.51-13.49
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-11.26-4.29-22.95-10.85-9.74-6.67-33.51-13.49
Net Income From Continuing Operations-11.26-4.29-22.95-10.85-9.74-6.67-33.51-13.49
Net Income-11.26-4.29-22.95-10.85-9.74-6.67-33.51-13.49
EPS (Recurring)-0.26-0.24-0.42-0.27-0.24-0.24-0.79-0.62
EPS (Basic, Before Extraordinaries)-0.31-0.12-0.72-0.34-0.30-0.26-1.93-0.98
EPS (Diluted)-0.31-0.12-0.72-0.34-0.30-0.26-1.93-0.98
EBITDA-8.42-9.70-9.39-7.09-6.48-5.43-4.86-6.04
Non-Operating Income (Expense)0.160.150.510.220.120.160.150.05
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.660.610.720.520.500.470.500.45
Price To Sales Ratio129.8458.0959.3124.1622.7220.4621.9955.13
Gross Margin-202.51-1,892.19-4.13-162.69-36.4940.272.86-233.04
Operating Margin-3,802.51-32,284.38-873.57-2,950.00-1,358.69-276.89-364.94-5,543.48
Net Margin-4,711.30-13,406.25-2,015.36-4,174.62-1,880.69-312.02-2,255.11-11,733.04
Shares Outstanding32.6232.2928.6828.6328.6228.6017.4513.37
Market Capitalization80.83105.51214.9895.0286.3787.5140.0738.12

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments12.318.649.4320.4333.857.8222.458.468.36
Short Term Receivables1.131.610.482.011.440.200.000.000.00
Inventories0.450.410.000.000.000.000.000.000.00
Other Current Assets1.420.820.783.103.851.210.510.180.17
Total Current Assets15.3111.4810.7025.5439.149.2322.968.648.53
Net Property, Plant & Equipment9.256.325.4410.858.376.523.730.610.82
Total Investments and Advances0.611.701.701.701.7015.1212.660.000.00
Intangible Assets0.0014.6156.5961.6380.4124.20-0.000.75
Other Assets0.590.970.460.3729.950.360.510.260.12
Total Assets25.7635.0874.89100.09159.5655.4239.869.5210.22
Short Term Debt Incl. Current Port. of LT Debt1.811.290.670.812.132.811.351.191.14
Accounts Payable2.541.640.951.251.810.430.470.170.17
Other Current Liabilities7.724.345.5810.0410.185.752.624.213.14
Total Current Liabilities12.077.287.1912.1114.129.004.445.564.45
Long Term Debt1.692.372.202.733.545.824.580.531.36
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities43.4537.7139.9045.6676.687.120.000.000.00
Total Liabilities57.2247.3549.3060.5094.3521.949.026.095.81
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.005.135.300.000.000.000.000.00
Common Equity-31.46-12.2720.4734.2965.2233.4830.843.424.40
Total Shareholders Equity-31.46-12.2725.5939.5965.2233.4830.843.424.40
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-31.46-12.2725.5939.5965.2233.4830.843.424.40
Total Liabilities & Stockholders Equity25.7635.0874.89100.09159.5655.4239.869.5210.22
Book Value Per Share-1.10-0.702.485.7814.149.6910.811.682.80
Tangible Book Value Per Share-1.10-1.54-4.37-4.61-3.292.6910.811.682.33
Full-Time Employees5849467611551331216
Price to Book Ratio-3.783.280.550.503.074.934.1616.3918.15
Return on Assets-165.10-110.32-28.41-14.34-40.57-62.83-90.84-159.66-157.12
Return on Equity--910.86-76.26-35.52-88.37-93.07-130.91-402.61-271.64
Return on Invested Capital---99.94-172.25-93.22-76.16-63.32-398.13-336.25
Quick Ratio1.231.521.492.112.771.035.171.551.91
Current Ratio1.271.581.492.112.771.035.171.551.91

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-49.36-50.22-60.66-27.78-72.90-64.10-29.93-22.43-15.75
Depreciation2.442.201.561.685.224.210.390.340.56
Other Funds (Non Cash)16.0523.1139.706.7524.0633.064.413.922.55
Funds from Operations-30.86-24.91-19.40-19.35-43.63-36.09-26.38-18.16-12.64
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital3.912.73-1.29-3.97-1.940.150.40-1.550.99
Cash from Operating Activities-26.95-22.18-20.69-23.32-45.57-35.94-25.98-19.71-11.65
Capital Expenditures-3.92-3.19-0.52-0.28-4.34-2.25-1.23-0.92-0.03
Net Assets From Acquisitions0.000.000.000.000.00-11.71-6.190.000.00
Sale of Fixed Assets and Businesses0.000.000.000.350.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.370.000.00-4.00-11.240.00
Purchase of Investments0.000.000.000.000.000.00-4.00-11.240.00
Sale Or Maturity of Investments0.000.000.000.370.000.000.000.000.00
Other Uses0.000.000.00-1.370.000.00-0.33-0.250.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities-3.92-3.19-0.51-0.93-4.34-13.96-11.75-12.41-0.03
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock24.6728.6621.0512.3037.2480.5322.1946.5113.29
Repurchase of Common Pref Stock0.000.00-5.39-1.120.000.000.000.000.00
Sale of Common Pref Stock24.6728.6626.4413.4237.2480.5322.1946.5113.29
Proceedsfrom Stock Options24.6628.6626.4413.4237.2475.3120.7545.569.64
Issuance or Reduction of Debt, Net-0.59-0.51-0.20-0.12-1.43-1.530.691.36-1.18
Change in Long Term Debt-0.59-0.51-0.20-0.12-1.43-1.530.691.36-1.18
Issuance of Long Term Debt0.000.000.000.000.000.001.143.000.00
Reduction of Long Term Debt-0.59-0.51-0.20-0.12-1.43-1.53-0.45-1.64-1.18
Net Financing Active Other Cash Flow-0.31-0.07-0.420.00-0.00-0.63-0.090.000.00
Other Financing Activities Uses-0.31-0.07-0.420.00-0.00-0.63-0.090.000.00
Cash from Financing Activities23.7628.0720.4312.1935.8178.3622.8047.8712.11
Exchange Rate Effect--0.12-0.02------
Net Change in Cash-7.262.58-0.80-12.07-14.1028.46-14.9315.740.43
Free Cash Flow-30.88-25.37-21.20-23.61-49.91-38.19-27.21-20.63-11.68
Preferred Dividends (Cash Flow)-0.00---0.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.00-9.26-1.250.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments18.4828.9312.3119.4224.2931.03
Short Term Receivables0.190.161.130.260.513.54
Inventories0.210.380.450.470.690.46
Other Current Assets1.661.051.421.241.351.24
Total Current Assets20.5430.5215.3121.3926.8436.26
Net Property, Plant & Equipment8.108.919.256.496.677.16
Total Investments and Advances0.240.420.610.791.701.70
Intangible Assets--0.0014.6014.6014.60
Other Assets0.560.570.590.670.700.64
Total Assets29.4440.4325.7643.9450.5260.36
Short Term Debt Incl. Current Port. of LT Debt1.711.761.811.601.541.40
Accounts Payable1.871.612.541.061.282.28
Other Current Liabilities6.718.637.725.013.836.00
Total Current Liabilities10.2912.0112.077.666.659.68
Long Term Debt0.921.311.691.531.832.07
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities39.5437.8143.4543.9440.9338.38
Total Liabilities50.7451.1257.2253.1349.4250.14
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-21.30-10.69-31.46-9.201.1010.22
Total Shareholders Equity-21.30-10.69-31.46-9.201.1010.22
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-21.30-10.69-31.46-9.201.1010.22
Total Liabilities & Stockholders Equity29.4440.4325.7643.9450.5260.36
Book Value Per Share-0.65-0.33-1.10-0.320.040.36
Tangible Book Value Per Share-0.65-0.33-1.10-0.83-0.47-0.15
Full-Time Employees--58---
Price to Book Ratio-3.78-2.99-23.3586.538.45-4.35
Return on Assets-123.46-94.93-165.10-106.49-101.28-88.64
Return on Equity----23,603.11-532.89-428.96
Return on Invested Capital-----332.26-54.27
Quick Ratio1.982.511.232.733.933.70
Current Ratio2.002.541.272.794.043.75

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-11.26-4.29-22.95-10.85-9.74-6.67
Depreciation0.670.630.560.580.560.49
Other Funds (Non Cash)2.96-5.2814.264.113.381.37
Funds from Operations-7.63-8.94-8.13-6.16-5.80-4.81
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-1.641.302.591.66-0.48-1.04
Cash from Operating Activities-9.27-7.64-5.54-4.50-6.28-5.86
Capital Expenditures-0.78-0.61-1.48-1.05-0.35-0.31
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.78-0.61-1.48-1.05-0.35-0.31
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock-0.1724.840.000.000.0028.66
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock-0.1724.840.000.000.0028.66
Proceedsfrom Stock Options-0.1824.840.000.000.0028.66
Issuance or Reduction of Debt, Net-0.15-0.14-0.18-0.12-0.11-0.10
Change in Long Term Debt-0.15-0.14-0.18-0.12-0.11-0.10
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt-0.15-0.14-0.18-0.12-0.11-0.10
Net Financing Active Other Cash Flow-0.240.00-0.070.000.000.00
Other Financing Activities Uses-0.240.00-0.070.000.000.00
Cash from Financing Activities-0.5624.70-0.25-0.12-0.1128.56
Exchange Rate Effect-0.02-0.01----
Net Change in Cash-10.6316.44-7.29-5.78-6.7422.39
Free Cash Flow-10.05-8.25-7.02-5.55-6.63-6.17

Revenue breakdown

Kitted Products2025: 24.00K
Laboratory Developed Test Services2024: 22.00K
Laboratory Services2024: 1.86M 2025: 4.03M
Asia Pacific2024: 145.00K
Europe2024: 18.00K 2025: 24.00K
United Kingdom2024: 45.00K
United States2024: 1.67M 2025: 4.03M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.03%1.0M10.2M245.43K
2026-10-159.29%0.9M10.2M227.20K
2026-09-309.52%1.0M10.2M224.61K
2026-09-159.71%1.0M10.2M206.84K
2026-08-319.11%0.9M10.2M216.78K
2026-08-1410.66%1.1M10.2M255.14K
2026-07-3110.65%1.1M10.1M298.23K
2026-07-1512.36%1.2M10.1M352.00K
2026-06-3010.02%1.0M10.1M380.73K
2026-06-1511.41%1.1M10.1M374.63K
2026-05-2910.11%1.3M12.7M348.01K
2026-05-159.35%1.2M12.7M311.42K
2026-04-307.05%0.7M10.1M228.23K
2026-04-151.63%0.5M28.0M167.01K
2026-03-311.31%0.4M28.0M110.50K
2026-03-130.66%0.2M28.0M59.21K
2026-02-270.78%0.2M25.0M48.14K
2026-02-130.91%0.2M25.0M50.77K
2026-01-300.90%0.2M25.0M53.82K
2026-01-150.82%0.2M25.0M69.91K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.004.904.000.0002.000.000.0000.0000.000
call2.000.004.900.000.0000.000.000.0000.0000.000
call3.000.004.900.000.0000.000.000.370-0.0190.001
call4.000.000.100.100.0003.000.000.0000.0000.000
call5.000.000.050.004.0060.000.000.219-0.0240.001
call6.000.004.902.134.3926.000.000.201-0.0250.001
call7.000.004.900.704.84525.000.000.189-0.0270.001
call8.000.004.900.005.2210.000.000.181-0.0280.001
call10.000.004.900.005.8210.000.000.170-0.0300.001
call11.000.004.900.006.0670.000.000.166-0.0310.001
call12.000.004.900.006.2880.000.000.163-0.0320.001
call13.000.004.901.006.4871.000.000.160-0.0320.001
put1.000.004.900.000.0000.000.000.0000.0000.000
put2.000.004.900.002.5530.000.00-0.259-0.0160.001
put3.000.004.900.500.0002.000.000.0000.0000.000
put4.000.004.901.000.0002.000.000.0000.0000.000
put5.000.004.900.000.0000.000.00-0.782-0.0230.001
put6.001.005.902.5027.3734.000.00-0.905-0.0110.001
put7.002.006.902.7527.7580.000.00-0.912-0.0120.001
put8.003.007.900.0028.1030.000.00-0.917-0.0120.001
put10.005.009.905.6628.6780.000.00-0.923-0.0130.001
put11.006.0010.900.0028.9290.000.00-0.926-0.0130.001
put12.007.0011.900.0029.1610.000.00-0.928-0.0130.001
put13.008.0012.900.0029.3770.000.00-0.929-0.0130.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-09-218-KCurrent report2026-09-15SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-07-24S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-178-KCurrent report2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-05-138-KCurrent report2026-05-13SEC
2026-05-138-K/A2026-02-20SEC
2026-04-30ARSAnnual report to security holders. 2025-12-31SEC
2026-04-30DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-04-30SEC
2026-04-308-KCurrent report2026-04-30SEC
2026-04-27SCHEDULE 13D/ASEC
2026-04-274Statement of changes in beneficial ownership of securities2026-04-23SEC
2026-04-204Statement of changes in beneficial ownership of securities2026-04-16SEC
2026-03-304Statement of changes in beneficial ownership of securities2026-03-26SEC
2026-03-304Statement of changes in beneficial ownership of securities2026-03-26SEC
2026-03-304Statement of changes in beneficial ownership of securities2026-03-26SEC
2026-03-2610-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-268-KCurrent report2026-03-26SEC
2026-02-268-KCurrent report2026-02-20SEC
2026-02-128-KCurrent report2026-02-10SEC
2026-02-12SCHEDULE 13D/ASEC
2026-02-124Statement of changes in beneficial ownership of securities2026-02-10SEC
2026-02-11424B5SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-042.69M600
2026-030000
2026-023.00M100
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
BROADWOOD CAPITAL INC39.28%
AWM Investment Company, Inc.8.78%
VANGUARD CAPITAL MANAGEMENT LLC2.28%
Family Office Research LLC1.99%
PURA VIDA INVESTMENTS, LLC1.50%
GEODE CAPITAL MANAGEMENT, LLC0.83%
FNY Investment Advisers, LLC0.74%
JANE STREET GROUP, LLC0.49%
BlackRock, Inc.0.47%
VANGUARD FIDUCIARY TRUST CO0.39%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.47%
VANGUARD EXTENDED MARKET INDEX FUND0.77%
Fidelity Extended Market Index Fund0.33%
iShares Micro-Cap ETF0.13%
Fidelity Total Market Index Fund0.12%
Fidelity Series Total Market Index Fund0.11%
Fidelity Nasdaq Composite Index Fund0.04%
VANGUARD BALANCED INDEX FUND0.02%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.01%
1290 VT Micro Cap Portfolio0.01%

OakChart. IMDX. Cached 15 minutes.